Get the Stockscreener App
54.09
3.26%
-1.82
After Hours:
54.44
0.35
+0.65%
Biomarin Pharmaceutical Inc stock is traded at $54.09, with a volume of 1.93M.
It is down -3.26% in the last 24 hours and down -4.87% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$55.91
Open:
$55.65
24h Volume:
1.93M
Relative Volume:
0.93
Market Cap:
$10.39B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
20.11
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
-6.37%
1M Performance:
-4.87%
6M Performance:
-23.32%
1Y Performance:
-35.90%
1-Day Range:
$54.05
$56.07
1-Week Range:
$54.05
$57.77
52-Week Range:
$52.93
$85.00
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
54.09 | 10.46B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Clearline Capital LP Sells 96,429 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Teza Capital Management LLC Makes New $723,000 Investment in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Federation des caisses Desjardins du Quebec Has $1.52 Million Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Bayforest Capital Ltd Invests $552,000 in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Parkman Healthcare Partners LLC Buys Shares of 277,252 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
NFJ Investment Group LLC Buys New Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
28,736 Shares in BioMarin Pharmaceutical Inc. $BMRN Bought by Cinctive Capital Management LP - MarketBeat
Vident Advisory LLC Takes Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
HC Wainwright Begins Coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) - MarketBeat
Narrow-Moat BioMarin Supported by Voxzogo and Rare-Disease Pipeline - Morningstar
Biomarin at Morgan Stanley Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
Biomarin at Morgan Stanley Conference: Strategic Growth and Innovation - Investing.com
Graham Capital Management L.P. Takes Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
AQR Capital Management LLC Purchases 1,642,206 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting - Lelezard
Are Options Traders Betting on a Big Move in BioMarin Pharmaceutical Stock? - sharewise.com
PTC Therapeutics To Challenge BioMarin's Metabolic Disorder TreatmentBioMarin Pharmaceutical (NASDAQ:BMRN) - Benzinga
Why BioMarin Pharmaceutical (BMRN) Stock Is Down Today - Yahoo Finance
BioMarin Says Data Showing Voxzogo's Benefits in Children With Achondroplasia - MarketScreener
This Duolingo Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by Raymond James Financial - MarketBeat
BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - MSN
Cubist Systematic Strategies LLC Invests $11.69 Million in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin’s PKU drug shows nearly 50% blood Phe reduction in teens - Investing.com Nigeria
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism - PR Newswire
Why is BioMarin Pharmaceutical Inc. stock going upInflation Watch & Fast Moving Market Watchlists - خودرو بانک
Canada Pension Plan Investment Board Increases Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
What is BioMarin Pharmaceutical Inc.’s book value per shareJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - خودرو بانک
What makes BioMarin Pharmaceutical Inc. stock price move sharply2025 Pullback Review & AI Driven Stock Reports - Newser
Is BioMarin Pharmaceutical Inc. stock influenced by commodity prices2025 Bull vs Bear & Detailed Earnings Play Strategies - خودرو بانک
What’s the outlook for BioMarin Pharmaceutical Inc.’s sector2025 Sector Review & Fast Moving Trade Plans - خودرو بانک
BioMarin Pharmaceutical Inc. stock daily chart insightsWeekly Trade Analysis & Verified Trade Idea Suggestions - Newser
Analyzing drawdowns of BioMarin Pharmaceutical Inc. with statistical toolsWeekly Trade Recap & Entry Point Confirmation Alerts - Newser
How to use a screener to detect BioMarin Pharmaceutical Inc. breakoutsJuly 2025 Technicals & Verified Entry Point Signals - Newser
Northwestern Mutual Wealth Management Co. Sells 4,768 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Tick level data insight on BioMarin Pharmaceutical Inc. volatilityJuly 2025 PostEarnings & Technical Pattern Alert System - Newser
What moving averages say about BioMarin Pharmaceutical Inc.July 2025 Big Picture & Weekly High Return Stock Forecasts - Newser
BioMarin at Wells Fargo Conference: Strategic Focus on Rare Diseases - Investing.com
What machine learning models say about BioMarin Pharmaceutical Inc.Earnings Risk Summary & High Accuracy Buy Signal Tips - Newser
Will BioMarin Pharmaceutical Inc. bounce back from current supportJuly 2025 Action & Community Consensus Picks - Newser
Visual trend scoring systems applied to BioMarin Pharmaceutical Inc.2025 Year in Review & Technical Confirmation Trade Alerts - Newser
Kodai Capital Management LP Invests $4 Million in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Technical signs of recovery in BioMarin Pharmaceutical Inc.July 2025 Closing Moves & Free Safe Entry Trade Signal Reports - Newser
Will BioMarin Pharmaceutical Inc. price bounce be sustainableMarket Performance Recap & Real-Time Sentiment Analysis - Newser
Top chart patterns to watch in BioMarin Pharmaceutical Inc.Take Profit & Risk Adjusted Buy/Sell Alerts - Newser
What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)? - MSN
BioMarin Pharmaceutical shares fall 1.15% after-hours following analyst presentation at Cantor Global. - AInvest
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
BioMarin’s Strategic Position in the 2025 Healthcare Innovation Landscape - AInvest
Will BioMarin Pharmaceutical Inc. outperform small cap indexesPortfolio Update Report & Stock Market Timing Techniques - خودرو بانک
Can you recover from losses in BioMarin Pharmaceutical Inc.2025 AllTime Highs & Safe Capital Growth Trade Ideas - Newser
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):